{"id":40,"date":"2016-04-05T22:31:14","date_gmt":"2016-04-05T22:31:14","guid":{"rendered":"http:\/\/projects.nib.si\/gammadeltatcells\/?page_id=40"},"modified":"2024-03-04T21:57:28","modified_gmt":"2024-03-04T20:57:28","slug":"short-description","status":"publish","type":"page","link":"https:\/\/projects.nib.si\/gammadeltatcells\/","title":{"rendered":"Short description"},"content":{"rendered":"<p>Chimeric Antigen Receptor (CAR)-T cell therapy is a clinically approved cancer immunotherapy approach using genetically engineered T cells and represents a paradigm shift in the treatment of certain blood cancers that do not respond to other available treatment options. However, the success of CAR-T cells has been met with challenges regarding efficacy, safety, and broad availability. Currently clinically approved CAR-T cells are derived from autologous (patient\u2019s own) T cells and focus on \u03b1\u03b2 T cell subsets. In this proposal, we investigate alternative immune cells called gamma delta (\u03b3\u03b4) T cells and explore their potential for cancer immunotherapy.<\/p>\n<p>This project combines clinical work and basic academic research to tackle complex challenges of \u03b3\u03b4 T cell biology in cancer immunotherapy and immune-mediated disorders. Therefore, the team is composed of researchers from two Slovenian groups that uniquely combine basic and clinical research.<\/p>\n<p>Coordinator: National Institute of Biology<\/p>\n<p>Partner 1: University Medical Center Ljubljana, University Children&#8217;s Hospital, Department of Allergology, Rheumatology and Clinical Immunology<\/p>\n<p>This project is financed by the\u00a0<a href=\"https:\/\/www.arrs.gov.si\/en\/index.asp\" target=\"_blank\" rel=\"noopener\">Slovenian Research and Innovation agency (ARIS)<\/a>.<br \/>\nProject ID: J3-50109<br \/>\nDuration: 1.10.2023 &#8211; 30.9.2026<\/p>\n<p><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" class=\"alignnone\" src=\"https:\/\/i0.wp.com\/pbs.twimg.com\/profile_images\/1696069698289332224\/tB-Z74Tn_400x400.jpg?resize=298%2C298&#038;ssl=1\" alt=\"ARIS (@aris_rfo) \/ X\" width=\"298\" height=\"298\" \/><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chimeric Antigen Receptor (CAR)-T cell therapy is a clinically approved cancer immunotherapy approach using genetically engineered T cells and represents a paradigm shift in the treatment of certain blood cancers that do not respond to other available treatment options. However, the success of CAR-T cells has been met with challenges regarding efficacy, safety, and broad [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"jetpack_post_was_ever_published":false,"footnotes":""},"class_list":["post-40","page","type-page","status-publish","hentry"],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/Phau4X-E","jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/projects.nib.si\/gammadeltatcells\/wp-json\/wp\/v2\/pages\/40","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/projects.nib.si\/gammadeltatcells\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/projects.nib.si\/gammadeltatcells\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/projects.nib.si\/gammadeltatcells\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/projects.nib.si\/gammadeltatcells\/wp-json\/wp\/v2\/comments?post=40"}],"version-history":[{"count":24,"href":"https:\/\/projects.nib.si\/gammadeltatcells\/wp-json\/wp\/v2\/pages\/40\/revisions"}],"predecessor-version":[{"id":380,"href":"https:\/\/projects.nib.si\/gammadeltatcells\/wp-json\/wp\/v2\/pages\/40\/revisions\/380"}],"wp:attachment":[{"href":"https:\/\/projects.nib.si\/gammadeltatcells\/wp-json\/wp\/v2\/media?parent=40"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}